Young People Get Osteoporosis Too 

Butterfly1b1  EVISTAButterfly1b5


Free E Cards • Email





Please be advised that the inclusion of any medication on this site is not indicative of an endorsement.  I do not have any affiliation with the pharmaceutical corporations that manufacture prescription osteoporosis medications.  I am not a doctor, therefore I am not medically qualified to counsel or advise osteoporosis patients about which medication is best suited for their individual case.

• actonel • aredia • boniva • didronel • evista • Forteo • fosamax • miacalcin • zometa • vivelle • reclast •

Visit the following link for more info about LillyAnswers

LillyAnswers Patient Assistance Program for Medicare enrolled seniors and those with disabilities

EVISTA is a prescription medication for the prevention and treatment of osteoporosis (thin, weak bones) in women after menopause.  EVISTA is also for women who have already been diagnosed with osteoporosis. It treats osteoporosis by helping make bones stronger and less likely to break. By increasing bone mass and strengthening your bones, EVISTA can reduce the risk of fracture, which can rob you of your independence and mobility.   As well preventing and treating osteoporosis, Evista also lowers cholesterol.  It lowers total cholesterol by about 7% and LDL (bad) cholesterol by about 11%.  It does not change HDL (good) cholesterol.  In clinical studies, women taking Evista had no increased risk of breast cancer.

Side effects
SIDE EFFECTS that may occur while taking this medicine include hot flashes or leg cramps. If they continue or are bothersome, check with your doctor. CHECK WITH YOUR DOCTOR AS SOON AS POSSIBLE if you experience swelling of hands, feet, or legs; breast pain or enlargement; unusual weight gain; or abnormal vaginal bleeding or spotting. CONTACT YOUR DOCTOR IMMEDIATELY if you experience pain in your calves, leg swelling, sudden chest pain, shortness of breath, or changes in vision. If you notice other effects not listed above, contact your doctor, nurse, or pharmacist.

Before using 

Some medicines or medical conditions may interact with this medicine. INFORM YOUR DOCTOR OR PHARMACIST of all prescription and over-the-counter medicine that you are taking. Inform your doctor of any other medical conditions, allergies, pregnancy, or breast-feeding. USE OF THIS MEDICINE IS NOT RECOMMENDED if you have a history of blood clots. Contact your doctor or pharmacist if you have any questions or concerns about taking this medicine.

Being immobile for long periods of time while taking this medicine may increase your risk of blood clots. During long periods of travel, get up and move around as often as possible. DO NOT SHARE THIS MEDICINE with others for whom it was not prescribed. 


Evista has been evaluated in three phase III trials in 1,764 postmenopausal women. These studies primarily investigated the effect of Evista on BMD of the lumbar spine and proximal femur.  Additional endpoints included effects on biochemical markers of bone turnover, and serum lipids. Only one of these studies has been published in full.  Data provided by the two unpublished studies are generally consistent with the following results.

The fully published European, double-blind, placebocontrolled trial randomised 601 postmenopausal women to Evista 30mg/day (n=152), 60mg/day (n=152), 150mg/day (n=147) or placebo (n=150).5   Compared with placebo, two years treatment with Evista 60mg/day significantly:

  • increased BMD at the lumbar spine, hip, femoral neck & total body, by 1-2%.

  • decreased the serum levels of biochemical markers of bone turnover.

  • decreased the serum concentrations of total and LDL cholesterol.

Data from the MORE study (n = 7,705) demonstrate that treatment with evista 60mg for 3 years,  reduced the risk of a new vertebral fracture in osteoporotic postmenopausal women by 30%. A reduction in the risk of hip or wrist fractures has not been demonstrated.

1. Eli Lilly and Company Limited. Evista. Summary of Product Characteristics 2000.
2. Fordham J. Treatment of established osteoporosis. Pharm J 2000;264:593-6.
3. Eastell R. Treatment of postmenopausal osteoporosis. N Engl JMed 1998;338:736-46.
4. Osteoporosis. Clinical guidelines for prevention and treatment. Royal College of Physicians of London. 1999.
5. Delmas P, Bjarnason N, Mitlak B, Ravoux A, Shah A, et al.Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal
women. N Engl J Med 1997;337:1641-7.
6. Walsh BW, Kuller LW, Wid RA, Paul S, Farmer M, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
7. Draper M, Flowers D, Huster W, Neild J, Harper K, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
8. Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45.
9. Davies G, Huster W, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-65.
10. Cummings S, Eckert S, Krueger K, Grady D, Powles T, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999;281:2189-97.
11. Cohen F, Watts S, Shah A, Akers R, Plouffe L. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000;95:104-10.
12. Goldstein S, Scheele W, Rajagopalan S, Wilkie J, Walsh B, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol